Skip to main content
. Author manuscript; available in PMC: 2013 Jun 5.
Published in final edited form as: J Natl Compr Canc Netw. 2013 Feb 1;11(2):161–169. doi: 10.6004/jnccn.2013.0024

Table 2.

First line clinical trials of 2nd generation TKI – unselected patients

Phase Population (number) Treatment Primary
endpoint		 Results
Dacomitinib
2 Advanced NSCLC, PD on chemo, no prior E (n=188) E or Dacomitinib PFS Prelim results: PFS, ORR favored D over E35
3 Advanced NSCLC, PD on chemo, no prior E (n=800, ongoing) E or Dacomitinib PFS None, actively recruiting patients
Vandetanib
3 Advanced NSCLC, previously treated (n=534) Peme +/− Vandetanib PFS Negative, no difference in PFS, although improved ORR (19% vs 8%)49
3 Advanced NSCLC, PD on 1st line platinum chemo (n=1391) Doce +/− Vandetanib PFS PFS 4mo w/Vandetanib vs 3mo, no OS difference50
BMS-690514
1/2 Advanced NSCLC, either E naïve or previous E w/ AR (n=60) BMS-690514 DCR, safety Prelim results: DCR 39% (11/28) in E naïve, 22% (7/32) E AR53
2 Advanced NSCLC, PD on 1st line platinum chemo (n=140) BMS-690514 vs Erlotinib PFS None